Article
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.
Blood advances - 12 Apr 2022
Knudsen Trine Alma, Skov Vibe, Stevenson Kristen, Werner Lillian, Duke William, Laurore Charles, Gibson Christopher J, Nag Anwesha, Thorner Aaron R, Wollison Bruce, Hansen Dennis Lund, Ellervik Christina, El Fassi Daniel, de Stricker Karin, Ocias Lukas Frans, Brabrand Mette, Bjerrum Ole Weis, Overgaard Ulrik Malthe, Frederiksen Mikael, Kristensen Thomas Kielsgaard, Kruse Torben A, Thomassen Mads, Mourits-Andersen Torben, Severinsen Marianne Tang, Stentoft Jesper, Starklint Joern, Neuberg Donna S, Kjaer Lasse, Larsen Thomas Stauffer, Hasselbalch Hans Carl, Lindsley R Coleman, Mullally Ann
Abstract excerpt
Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencing (NGS) on 202 pretreatment samples obtained from patients with MPN enrolled in the DALIAH trial (A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.